Vor Biopharma (VOR) – Research Analysts’ Recent Ratings Changes

A number of firms have modified their ratings and price targets on shares of Vor Biopharma (NASDAQ: VOR) recently:

• 5/18/2026 – Vor Biopharma had its “buy” rating reaffirmed by HC Wainwright. They now have a $31.00 price target on the stock.
• 5/16/2026 – Vor Biopharma was downgraded by Wall Street Zen from “hold” to “sell”.
• 5/14/2026 – Vor Biopharma had its price target raised by Wedbush from $15.00 to $18.00. They now have a “neutral” rating on the stock.
• 4/30/2026 – Vor Biopharma was upgraded by Jefferies Financial Group Inc. to “strong-buy”.
• 4/15/2026 – Vor Biopharma had its price target lowered by HC Wainwright from $32.00 to $31.00. They now have a “buy” rating on the stock.
• 4/4/2026 – Vor Biopharma was upgraded by Wall Street Zen from “strong sell” to “hold”.
• 3/31/2026 – Vor Biopharma had its price target raised by Wedbush to $15.00. They now have a “neutral” rating on the stock.
• 3/30/2026 – Vor Biopharma is now covered by Jefferies Financial Group Inc.. They set a “buy” rating and a $50.00 price target on the stock.
• 3/29/2026 – Vor Biopharma was upgraded by Jefferies Financial Group Inc. to “strong-buy”.

Insider Activity

In other Vor Biopharma news, Director Ra Capital Management, L.P. sold 165,150 shares of the firm’s stock in a transaction that occurred on Wednesday, April 22nd. The stock was sold at an average price of $15.77, for a total transaction of $2,604,415.50. Following the completion of the sale, the director owned 2,402,095 shares in the company, valued at $37,881,038.15. This trade represents a 6.43% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders sold a total of 3,002,903 shares of company stock valued at $49,412,176 in the last ninety days. 0.45% of the stock is currently owned by company insiders.

Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company’s proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient’s immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.

The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).